Short Biography

Jonathan D. Stallings, PhD is the Chief Data Scientist at the Joint Trauma System, where he leads efforts in data analysis and applying advanced statistical methods to improve trauma care. He is particularly interested in leveraging artificial intelligence (AI) for medical devices and navigating the regulatory approval process. He recently played a significant role in the FDA clearance of the DOD’s first AI medical device. His research also explores the use of generative AI to enhance data extraction, medical records review, and routine epidemiological studies.

Dr. Stallings retired from the U.S. Army as a Lieutenant Colonel, having served in various key roles that spanned 22 years of research, regulatory affairs, and operational medicine, which include deploying as a theater biochemist in the Middle East and a Fellowship at the FDA. Dr. Stallings continues to expand his expertise in biostatistics, applied statistics, data science, machine learning, and clinical trial analysis, with over 70 peer-reviewed publications. His military education includes Officer Basic Leadership Course, Medical Management of Chemical and Biological Casualties Course, Captain’s Career Course, Intermediate Medical Acquisitions Course, and Intermediate Level Education. He has obtained Level III Science & Technology Manager and Level II Program Management certification.

He is recognized for his contributions with multiple military awards, including the Legion of Merit, Meritorious Service Medal (3rd Award), Army Commendation Medal (3rd Award), Army Achievement Medal (4th Award), Joint Meritorious Unit Award, and the United Nations Medal. He was awarded the Brigadier General Michael A. Dunn “Press-On Energy” award, Order of Military Medical Merit, 8X-acquisitions, and 9A-professional designations, and the German Armed Forces Proficiency badge (Silver). He is married to Alexandra of Long Island, NY, and they reside in Converse, TX.

Contact us

Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!